Biological markers and prognosis in recurrent oral cancer after salvage surgery

Archives of Otolaryngology - Head and Neck Surgery

Volumn 134, Issue 7, 2008, Pages 743-749

  Agra, Ivan Marcelo Gonçalves ^a   Carvalho, André Lopes ^a   Pinto, Clovis Antônio Lopes ^b   Martins, Everton Pontes ^a,c   Filho, João Gonçalves ^a   Soares, Fernando Augusto ^b   Kowalski, Luiz Paulo ^a,d  

^a Departments of Head and Neck Surgery Otorhinolaryngology

^b Department of Pathology ^*

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TERTIARY HEALTH CARE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIP NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REOPERATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47949091883     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.134.7.743     Document Type: Article

References (21)

1. Carvalho AL, Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Dis. 2003;9(3):112-118.
2. Carvalho AL, Singh B, Spiro RH, Kowalski LP, Shah JP. Cancer of the oral cavity: a comparison between institutions in a developing and a developed nation. Head Neck. 2004;26(1):31-38.
3. Ridge JA. Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol. 1993;20(5):419-429.
4. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3, pt 2)(suppl 93):1-18.
5. Agra IM, Carvalho AL, Kowalski LP, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006;28(2):107-113.
6. Wong LY, Wei WI, Lam LK, Yuen APW. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25(11): 953-957.
7. de Visscher AVM, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity: does it make sense? Arch Otolaryngol Head Neck Surg. 1994;120(9):934-939.
8. Rosenthal EL, Matrysian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006;28(7):639-648.
9. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006;1:11.
10. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.
11. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
12. Llewelyn J, Mitchell R. Survival of patients who needed salvage surgery for recurrence after radiotherapy for oral carcinoma. Br J Oral Maxillofac Surg. 1997; 35(6):424-428.
13. Stell PM. Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck. 1991;13(4):277-281.
14. Kim SH, Cho NX, Kim K, et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol. 2006;93(4):330-337.
15. Katayama A, Bondoh N, Kishibe K, et al. Expression of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastasis and prognosis. Clin Cancer Res. 2004;10(2):634-640.
16. Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinases-2 and -9 activities correlate with disease-free survival of oral squamous cell carcinoma patients. Int J Oncol. 2002;20(1):189-194.
17. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(9):624-630.
18. Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434-1440.
19. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350-7356.
20. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer. 2003;89(4):681-686.
21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.